סנדוסטטין 0.5 מגמל Israel - hebreiska - Ministry of Health

סנדוסטטין 0.5 מגמל

novartis israel ltd - octreotide - תמיסה להזרקה\אינפוזיה - octreotide 0.5 mg/ml - octreotide - octreotide - prevention of complications following pancreatic surgery. symptomatic control and reduction of gh and igf-1plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. sandostatin treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery or in the interim period until radiotherapy becomes fully effective. relief of symptoms associated with functional gastroenteropancreatic endocrine tumours: carcinoid tumours with features of the carcinoid syndrome. vipomas . glucagonomas . gastrinomas / zollinger-ellison syndrome usually in conjunction with proton pump inhibitors or h2- antagonist therapy . insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy . grfomas. sandostatin is not an antitumour therapy and is not curative in these patients.emergency management of bleeding gastro-oesophageal varices secondary to cirrhosis in combination with specific therapy such as endoscopic sclerotherapy.

סנדוסטטין 30 מג LAR Israel - hebreiska - Ministry of Health

סנדוסטטין 30 מג lar

novartis israel ltd - octreotide - אבקה וממס להכנת תרחיף להזרקה - octreotide 30 mg - octreotide - octreotide - treatment of acromegaly in: patients already adequately controlled on standard doses of sandostatin s.c. patients in whom surgery or radiotherapy are inappropriate or ineffective, or who are in the latency period before radiotherapy becomes fully effective.endocrine gastro-entero- pancreatic (gep) tumors, carcinoid tumors.

סנדוסטטין  20 מג LAR Israel - hebreiska - Ministry of Health

סנדוסטטין 20 מג lar

novartis israel ltd - octreotide - אבקה וממס להכנת תרחיף להזרקה - octreotide 20 mg - octreotide - octreotide - treatment of acromegaly in: patients already adequately controlled on standard doses of sandostatin s.c. patients in whom surgery or radiotherapy are inappropriate or ineffective, or who are in the latency period before radiotherapy becomes fully effective. endocrine gastro-entero- pancreatic (gep) tumors, carcinoid tumors.

סנדוסטטין  10 מג LAR Israel - hebreiska - Ministry of Health

סנדוסטטין 10 מג lar

novartis israel ltd - octreotide - אבקה וממס להכנת תרחיף להזרקה - octreotide 10 mg - octreotide - octreotide - treatment of acromegaly in: patients already adequately controlled on standard doses of sandostatin s.c. patients in whom surgery or radiotherapy are inappropriate or ineffective, or who are in the latency period before radiotherapy becomes fully effective. endocrine gastro-entero- pancreatic (gep) tumors, carcinoid tumors.

סנדוסטטין   0.2 מגמל Israel - hebreiska - Ministry of Health

סנדוסטטין 0.2 מגמל

novartis israel ltd - octreotide - תמיסה להזרקה\אינפוזיה - octreotide 0.2 mg/ml - octreotide - octreotide - prevention of complications following pancreatic surgery. symptomatic control and reduction of gh and igf-1plasma levels in patients with acromegaly who are inadequately controlled by surgery or radiotherapy. sandostatin treatment is also indicated for acromegalic patients unfit or unwilling to undergo surgery or in the interim period until radiotherapy becomes fully effective. relief of symptoms associated with functional gastroenteropancreatic endocrine tumours: - carcinoid tumours with features of the carcinoid syndrome - vipomas - glucagonomas - gastrinomas / zollinger-ellison syndrome usually in conjunction with proton pump inhibitors or h2- antagonist therapy - insulinomas for pre-operative control of hypoglycaemia and for maintenance therapy - grfomas. sandostatin is not an antitumour therapy and is not curative in these patients.emergency management of bleeding gastro-oesophageal varices secondary to cirrhosis in combination with specific therapy such as endoscopic sclerotherapy.

אומניטרופ 10 מג \1.5 מל Israel - hebreiska - Ministry of Health

אומניטרופ 10 מג \1.5 מל

novartis israel ltd - somatropin recombinant - תמיסה להזרקה - somatropin recombinant 10 mg / 1.5 ml - somatropin

אומניטרופ 15 מג \1.5 מל Israel - hebreiska - Ministry of Health

אומניטרופ 15 מג \1.5 מל

novartis israel ltd - somatropin recombinant - תמיסה להזרקה - somatropin recombinant 15 mg / 1.5 ml - somatropin

אומניטרופ 5 מג \1.5 מל Israel - hebreiska - Ministry of Health

אומניטרופ 5 מג \1.5 מל

masrouji co, ltd - somatropin recombinant - תמיסה להזרקה - somatropin recombinant 5 mg / 1.5 ml - somatropin

אקסלון מדבקה 10 Israel - hebreiska - Ministry of Health

אקסלון מדבקה 10

novartis israel ltd - rivastigmine - מדבקות - rivastigmine 9.5 mg/day - rivastigmine

אקסלון מדבקה 15 Israel - hebreiska - Ministry of Health

אקסלון מדבקה 15

novartis israel ltd - rivastigmine - מדבקות - rivastigmine 27 mg - rivastigmine